Table 1 |
||||
|
International Breast Cancer Study Group tailored treatment trials (trials presented in this report) |
||||
| IBCSG Trial |
Population |
Activation |
Target accrual |
Comparison(s) |
|
|
||||
| CM-maintenance IBCSG 22-00 |
Endocrine non-responsive |
November 2000 |
900 |
Induction CT versus Induction CT → CM maintenance |
| CASA IBCSG 32-05 |
Endocrine non-responsive, older, not suitable for standard CT |
August 2005 |
1,296 |
Option 1: PLD versus nil Option 2: PLD versus low dose CM |
| SOFT IBCSG 24-02 |
Premenopausal at randomization |
August 2003 |
3,000 |
Tamoxifen alone versus OFS + tamoxifen versus OFS + exemestane |
| TEXT IBCSG 25-02 |
Should get OFS at start |
August 2003 |
1,845 |
Triptorelin ± CT + tamoxifen versus triptorelin ± CT + exemestane |
| PERCHE IBCSG 26-02 |
Should get OFS at start, lower risk |
August 2003 |
1,750 |
OFS + (tamoxifen or exemestane) versus OFS + CT + (tamoxifen or exemestane) |
|
|
||||
|
CM, cyclophosphamide and methotrexate; CT = chemotherapy; IBCSG = International Breast Cancer Study Group; OFS = ovarian function suppression; PLD = pegylated liposomal doxorubicin. |
||||
|
Price et al. Breast Cancer Research 2005 7:252 doi:10.1186/bcr1334 |
||||